Mobile Menu - OpenMobile Menu - Closed

“Assessing VA’s Risks for Drug Diversion”

“Assessing VA’s Risks for Drug Diversion”
Date: 
Monday, February 27, 2017 - 3:30pm
Location: 
334 Cannon House Office Building, Washington, DC 20515

Witnesses

Keith Berge, M.D.
Consultant in Anesthesiology, Chair, Mayo Clinic Enterprise-wide Medication Diversion Prevention Committee, on behalf of Mayo Clinic

Carolyn Clancy, M.D.
Deputy Under Secretary for Health for Organizational Excellence, Veterans Health Administration, on behalf of U.S. Department of Veterans Affairs

Nick Dahl
Deputy Assistant Inspector General for Audits and Evaluations, on behalf of VA Office of Inspector General

Michael H. Valentino, R. Ph. , MHSA
(Accompanying Dr. Lynch) Chief Consultant, Veterans Health Administration, Pharmacy Benefits Management Services, on behalf of U.S. Department of Veterans Affairs

Emorfia Valkanos, R. Ph.
(Accompanying Mr. Dahl) Health Systems Specialist, Office of Healthcare Inspections, on behalf of VA Office of Inspector General

Randall B. Williamson
Director, Healthcare Team, U.S. Government Accountability Office, on behalf of U.S. Government Accountability Office

115th Congress